Calton & Associates’s Halozyme HALO Stock Holding History

Calton & Associates’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-268	Closed	-$5K	–	721
2017 Q4	$5K	Buy	+268	New	+$4.93K	﹤0.01%	1246

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calton & Associates's HALO Position: Q1 2018 in Review

Calton & Associates sold out of Halozyme (HALO) in Q1 2018, closing a stake of 268 shares — an estimated $5K sold.

Calton & Associates first reported a position in HALO in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 209 funds tracked by Wall St. Rank hold HALO as of Q1 2018.

Calton & Associates reported no remaining Halozyme position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 268 Halozyme shares in Q1 2018, an estimated $5K.
Calton & Associates first reported a position in Halozyme in Q4 2017 and held it in 1 quarter.
Calton & Associates's Halozyme position peaked at $5K in Q4 2017.
209 funds tracked by Wall St. Rank held Halozyme as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.